Expert in benign prostatic hyperplasia (BPH).
Dr. Enrique Rijo completed his Urology residency at the Hospital del MarThis link will open in a new window, Barcelona, in 2011, where he worked as an Associate Urologist and Associate Professor of Urology at the Universitat Autònoma de BarcelonaThis link will open in a new window until 2015.
He obtained the degree of Doctor of Medicine from the Universitat de BarcelonaThis link will open in a new window and his doctoral thesis received the award for "Best Doctoral Thesis approved and read in 2017" by the Spanish Association of Urology (AEU) and the Foundation for Research in Urology (FIU).
He has worked in the Hospitals of the QuirónSalud groupThis link will open in a new window: Hospital Quirón BarcelonaThis link will open in a new window for the last 5 years and recently also in Centro Médico Teknon.
He is a Fellow of the European Board of Urology (EBUF)This link will open in a new window and of the American College of Surgeons (FACS)This link will open in a new window.
Dr. Rijo specializes in BPH surgery and has extensive experience in endoscopic laser enucleation of the prostate and other minimally invasive techniques.
In recent years he has worked as a trainer in green laser prostate enucleation technique (GreenLEP) and holmium laser prostate enucleation (HoLEP).
Selected publications from PubMed
Long-term outcomes after treatment with Optilume BPH Four-year results from the EVEREST study.
Kaplan SA, Pichardo M, Rijo E, Espino G, Lay RR, Estrella R
Can Urol Assoc J. 2024 Nov;18(11):E319-E325 doi: 10.5489/cuaj.8737.
Defining minimal invasive surgical therapy for benign prostatic obstruction surgery: Perspectives from a global knowledge, attitude, and practice survey.
Kwun-Chung Cheng B, Kar-Kei Yuen S, Castellani D, Wroclawski ML, Zhao H, Chiruvella M, Chua WJ, Tiong HY, Tanidir Y, Rosette J, Rijo E, Misrai V, Krambeck A, Elterman DS, Somani BK, Yuen-Chun Teoh J, Gauhar V
Asian J Urol. 2024 Jan;11(1):55-64 doi: 10.1016/j.ajur.2022.02.011.
Durable benefit after treatment of obstructive benign prostatic hyperplasia with a novel drug-device combination product: 2-year outcomes from the EVEREST-I study.
Pichardo M, Rijo E, Espino G, Lay RR, Estrella R, Gonzalez C, Fernandez M, Soriano D, Peralta IM, Kaplan SA
World J Urol. 2023 Aug;41(8):2209-2215 doi: 10.1007/s00345-023-04473-1.
The impact of 5-ARI on perioperative and functional outcomes of GreenLight PVP: an analysis of the Global GreenLight Group database.
Elsherbini T, Bouhadana D, Sadri I, Nguyen DD, Law KW, Arezki A, Deyirmendjian C, Ibrahim A, Bhojani N, Elterman DS, Chughtai B, Bruyère F, Cindolo L, Ferrari G, Vasquez-Lastra C, Borelli-Bovo T, Becher EF, Cash H, Reimann M, Rijo E, Misrai V, Zorn KC
Can J Urol. 2023 Apr;30(2):11473-11479.
Safety and efficacy of GreenLight PVP in octogenarians: evaluation of the Global GreenLight Group database.
Deyirmendjian C, Nguyen DD, Law KW, Nguyen AV, Sadri I, Arezki A, Bouhadana D, Ibrahim A, Bhojani N, Elterman DS, Chughtai B, Bruyère F, Cindolo L, Ferrari G, Vasquez-Lastra C, Borelli-Bovo T, Becher EF, Cash H, Reimann M, Rijo E, Misrai V, Zorn KC
World J Urol. 2023 Apr;41(4):1133-1140 doi: 10.1007/s00345-023-04334-x.
Dr. Enrique Rijo (Spain) and his team at the Hospital Quiron Barcelona (Spain) will perform an en-bloc HoLEP using MOSES 2.0. laser and answer all your questions.
With Boston Scientific
Published
Aug 2022
The less invasive Rezum treatment is, the higher the likelihood of meeting the patient's expectations regarding risks and benefits. That’s why performing less invasive Rezum treatments is recommended to achieve the greatest benefits when dealing with benign prostatic hyperplasia.
With Boston Scientific
Published
Nov 2021
Help your network discover Dr. Enrique Rijo's clinical expertise.
